Figure 5
4Mu preconditioning of HCC cells increases phagocytosis of Hepa129 cells by DCs promotes a potent antitumoral response. (a) DCs was derived from bone marrow of C3H/j mice, and incubated for 7 days in presence of GM-CSF and IL-4. Hepa129 cells were treated with 4Mu for 72 h. Phagocytosis assay of DCs was performed by incubation with DAPI + Hepa129 cell (1:4). The analysis of the percentage of MHCII+CD86+DAPI+ (right) was performed using flow cytometry *p < 0.05 4Mu vs. RPMI (left), Mann–Whitney test. Data are expressed as mean percentage ± SD. (b) C3Hj mice were s.c. inoculated with 1 × 106 Hepa 129 cells (n = 4–5/group); on day 9, mice were peritumorally injected with 1 × 106 4Mu-treated tumor-pulsed DCs, tumor-pulsed DCs o saline *p < 0.05 4Mu-treated Hepa 129-pulsed DCs vs. Saline; (c) Kaplan–Meier survival curve of the mice bearing Hepa 129 tumors. (d) BALB/c mice (n = 4/group) were s.c. inoculated with 1 × 106 BNL cells; on day 9, mice were peritumorally injected with 1 × 106 4Mu-treated BNL- pulsed DCs, BNL-pulsed DCs o saline. *p < 0.05 4Mu-treated BNL-pulsed DCs vs. Saline; ANOVA and Tukey’s test. (e) Kaplan–Meier survival curve of the mice bearing BNL tumors. Tumor volumes were measured 3 times a week over a period of 30 days. The growth curve is representative of 3 independent experiments (mean ± SD).
